Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.

Background: More than 400 preclinical studies report ≥ 1 compound as cytotoxic to multiple myeloma (MM) cells; however, few of these agents became relevant in the clinic. Thus, the utility of such assays in predicting future clinical value is debatable.

Patients And Methods: We examined the application of early-phase trial experiences to predict future clinical adoption.